Rami Manochakian: U.S. FDA approves Amivantamab + Chemotherapy for advanced EGFR+ NSCLC

Rami Manochakian shared a post on X:

“Hot off the press.

As expected (and already in guidelines); U.S. FDA approves Amivantamab + Chemotherapy for Treatment of advanced EGFR+ (Exon 19 or 21) non-small cell Lung Cancer after progression on TKI (Osimertinib).

Approval based on MARIPOSA2 study:

• high PFS (compared to chemo alone):
• 6.3 v 4.2 mos (HR 0.48).”

Read further.
Source: Rami Manochakian/X

Dr. Rami Manochakian is a thoracic medical oncologist at Mayo Clinic, Florida. He specializes in thoracic malignancies, including lung cancer, mesothelioma, and thymic tumors, he has dedicated his career to advancing the field of oncology.

He is also recognized as a leader in medical education, serving in various educational roles at Mayo Clinic and national and international medical societies, including ASCO, ALA, and IASLC.